Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival
- PMID: 7883423
- DOI: 10.1097/00004347-199501000-00006
Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival
Abstract
Clear cell carcinoma (CCC) and uterine papillary serous carcinoma (UPSC) are aggressive variants of endometrial carcinoma that may coexist or share some clinicopathologic features suggesting a similar biologic spectrum and the need for a common therapeutic approach. Twenty-nine cases of pathologic FIGO stage I and II CCC and 47 cases of FIGO stage I and II UPSC seen and treated at Yale-New Haven Hospital were reviewed, and the survival rates with regard to various pathological parameters were compared. Both groups of patients had similar clinical profiles with respect to presentation, age, weight, and medical problems. The 5-year survival for pathologic stage I patients with CCC was 72% and for those with UPSC 44%. The 5-year survival for pathologic stage II patients with CCC was 59% and for those with UPSC 32%. Analysis of survival showed that the depth of myometrial invasion, the presence of vascular space invasion, and the admixture of endometrioid features did not influence survival in either group of patients. In CCC, survival was also not influenced by the predominant histologic pattern, i.e., papillary versus nonpapillary. The results of this study suggest that early stage CCC and UPSC have similar clinicopathologic profiles, suggesting the need for aggressive approaches including a staging laparotomy and possibly similar therapy. However, the stage I CCC patients had a significantly better survival than the stage I UPSC patients.
Similar articles
-
Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study.J Gynecol Oncol. 2019 May;30(3):e44. doi: 10.3802/jgo.2019.30.e44. J Gynecol Oncol. 2019. PMID: 30887761 Free PMC article.
-
Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?Int J Gynecol Cancer. 2008 Jul-Aug;18(4):820-4. doi: 10.1111/j.1525-1438.2007.01082.x. Epub 2007 Sep 24. Int J Gynecol Cancer. 2008. PMID: 17892450 Clinical Trial.
-
Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.Anticancer Res. 1996 Mar-Apr;16(2):899-904. Anticancer Res. 1996. PMID: 8687148
-
Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy.Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):767-78. doi: 10.1016/s0360-3016(00)00724-0. Int J Radiat Oncol Biol Phys. 2000. PMID: 11020574 Review.
-
Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1272-6. doi: 10.1016/s0360-3016(02)04404-8. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654437 Review.
Cited by
-
Does tumor size have prognostic value in patients undergoing lymphadenectomy in endometrioid-type endometrial cancer confined to the uterine corpus?Turk J Med Sci. 2019 Oct 24;49(5):1403-1410. doi: 10.3906/sag-1902-224. Turk J Med Sci. 2019. PMID: 31650820 Free PMC article.
-
Age dependent association of endometrial polyps with increased risk of cancer involvement.World J Surg Oncol. 2005 Feb 9;3(1):8. doi: 10.1186/1477-7819-3-8. World J Surg Oncol. 2005. PMID: 15703068 Free PMC article.
-
The effect of cell type on surgico-pathologic risk factors in endometrial cancer.J Turk Ger Gynecol Assoc. 2011 Mar 1;12(1):9-14. doi: 10.5152/jtgga.2011.03. eCollection 2011. J Turk Ger Gynecol Assoc. 2011. PMID: 24591950 Free PMC article.
-
Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.Br J Cancer. 2006 Mar 13;94(5):642-6. doi: 10.1038/sj.bjc.6603012. Br J Cancer. 2006. PMID: 16495918 Free PMC article.
-
Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer.Br J Cancer. 2011 May 10;104(10):1611-8. doi: 10.1038/bjc.2011.80. Epub 2011 Apr 19. Br J Cancer. 2011. PMID: 21505452 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources